-
1 week ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) May 8 -- Chinese biopharmaceutical giant BeiGene has reported its first-ever quarterly profit under US Generally Accepted Accounting Principles thanks to robust worldwide sales of its two core cancer drugs and tighter cost controls. Beigene raked in GAAP net profit of USD1.27 million in the first quarter, according to the Beijing-based firm’s latest earnings report.
-
2 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) April 25 -- Sinopep-Allsino Biopharmaceutical retains competitive advantages despite the United States’ latest tariff hikes, according to the Chinese supplier of active pharmaceutical ingredients for glucagon-like peptide-1 drugs.
-
3 weeks ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) April 22 -- Fosun Pharmaceutical Group said the Chinese drugmaker plans to increase its stake in Henlius Biotech after its plan to take the firm private was rejected. Shares of both companies gained. Henlius [HKG: 2696] closed up 11.6 percent at HKD37.90 (USD4.89) a share in Hong Kong today, while Fosun Pharma [SHA: 600196; HKG: 2196] rose 2.1 percent to CNY24.40 (USD3.34) in Shanghai and 4 percent to HKD14.54 in Hong Kong.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) April 11 -- China's top drugs regulator has given the green light to a gene therapy developed by Belief BioMed's unit Xinzhi Medicine Technology for treating moderate-to-severe hemophilia B in adult patients, becoming the first such treatment approved in the country.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) April 3 -- The "reciprocal tariffs" on all US trading partners that President Donald Trump set out yesterday are unlikely to reduce the country’s reliance on China-made active pharmaceutical ingredients in the short term, though their export competitiveness may be weakened, according to industry experts.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) March 28 -- Shares in Shanghai Junshi Biosciences surged as much as 11.6 percent in Hong Kong today after the Chinese drugmaker reported that its net losses contracted 44 percent last year from the year before thanks to robust sales of its new cancer drug. Junshi’s Hong Kong-traded stock [HKG:1877] ended the day up 5 percent at HKD15.38 (USD2) after hitting HKD16.30 earlier in the day. In Shanghai, its share price [SHA:688180] closed up 1.41 percent at CNY30.24 (USD4.16).
-
1 month ago | 
yicaiglobal.com | Wang Zhen |Le Yan |He Tao |Lin Zhiyin
We sent you a codeEnter it below to verify via You'll need a passwordMake sure it's 8 characters or moreSHOW PASSWORD/HIDE PASSWORDSuccess! Welcome to Yicai GlobalFind your Yicai Global accountCheck your emailWe've sent an email to with a confirmation code. Enter the code below to reset your password. If you don't see the email, check your junk, spam or other folders. Change your passwordStrong passwords include numbers,letters,and special characters.
-
1 month ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) March 18 -- Chinese tech giant Tencent Holdings has started helping Shenzhen Third People's Hospital create targeted health check-up plans through artificial intelligence. The smart concierge service gathers health information from patients such as age, medical history, lifestyle habits, and work environment, and recommends targeted check-up plans for them, Yicai learned on the spot. The system goes beyond the usual questions placed in hospital reception.
-
2 months ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) March 14 -- Chinese drugmaker Fosun Pharmaceutical Group will sell United Family Healthcare to Calcite Gem Investments Group, an investment holding company owned by US private equity firm Warburg Pincus, for USD124.1 million. Fosun Pharma’s board of directors approved the sale of the company’s whole 9.4 million shares of United Family Healthcare for USD13.20 apiece to Calcite Gem, the Shanghai-based firm announced yesterday.
-
2 months ago | 
yicaiglobal.com | Lin Zhiyin
(Yicai) March 7 -- Chinese private equity giant Hillhouse Capital sold around HKD5 billion (USD643 million) worth of Beigene’s shares this week, cashing in on a 40 percent gain in the biotech firm’s stock price so far this year. Hillhouse’s HHLR Fund and Hillhouse BGN Holdings pared their stake in Beigene from 8.97 percent to 6.66 percent on March 3 and 4, selling around 32.2 million shares through block trading, Beijing-based Beigene said yesterday. This led to a slump in Beigene’s share price.
